China Biotech Services Holdings (HKSE:08037) ROCE % : -48.17% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is China Biotech Services Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China Biotech Services Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -48.17%.

China Biotech Services Holdings ROCE % Historical Data

The historical data trend for China Biotech Services Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biotech Services Holdings ROCE % Chart

China Biotech Services Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-31.52

42.09

33.70

123.65

-19.19

China Biotech Services Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															127.03	-1.13	-10.61	-29.61	-48.17

China Biotech Services Holdings ROCE % Calculation

China Biotech Services Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-136.714	/	( ( (1470.491 - 548.664)	+	(662.362 - 159.467) )	/ 2 )
	=	-136.714	/	( (921.827	+	502.895)	/ 2 )
	=	-136.714	/	712.361
	=	-19.19 %

China Biotech Services Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-242.248	/	( ( (0 - 0)	+	(662.362 - 159.467) )	/ 1 )
	=	-242.248	/	( ( 0	+	502.895 )	/ 1 )
	=	-242.248	/	502.895
	=	-48.17 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

China Biotech Services Holdings (HKSE:08037) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

China Biotech Services Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of China Biotech Services Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biotech Services Holdings (HKSE:08037) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

255-257 Gloucester Roaad, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG

Website

http://www.cbshhk.com

China Biotech Services Holdings Ltd is an investment holding company. It operates through six segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Securities, Insurance brokerage, BNCT and Others. It derives prime revenue from the Medical and health related services segment which involves the provision of medical laboratory testing and health check services. The group has a business presence in Hong Kong and the PRC, of which key revenue is generated from Hong Kong.

Executives

Liu Xiaolin	2101 Beneficial owner
Genius Earn Limited	2201 Interest of corporation controlled by you
Genius Lead Limited	2101 Beneficial owner
Guoyuan International Holdings Limited	2201 Interest of corporation controlled by you
Guoyuan Securities Co., Ltd.	2201 Interest of corporation controlled by you
Guoyuan Securities Investment (hong Kong) Limited	2101 Beneficial owner
Richlane Ventures Limited	2101 Beneficial owner
Ko Chun Shun, Johnson	2201 Interest of corporation controlled by you

China Biotech Services Holdings (HKSE:08037) Headlines

No Headlines